Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Preferred Stock Liabilities (2021 - 2022)

Prime Medicine (PRME) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $395.8 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Preferred Stock Liabilities changed N/A year-over-year to $395.8 million, compared with a TTM value of $395.8 million through Sep 2022, changed N/A, and an annual FY2021 reading of $395.8 million, up 1171.2% over the prior year.
  • Preferred Stock Liabilities was $395.8 million for Q3 2022 at Prime Medicine, up from $199.6 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $395.8 million in Q4 2021 and bottomed at $199.6 million in Q1 2022.